Combination Therapy for Urea Cycle Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for urea cycle disorders (UCDs) rely heavily on expensive nitrogen-scavenging medications like phenylbutyrate, with limited comparative efficacy studies and high economic burden, necessitating a cost-effective management strategy.
Innovation Solution
Combination therapy using phenylbutyrate and benzoate, administered at specific doses and ratios, to enhance nitrogen excretion and reduce treatment costs without compromising efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If phenylbutyrate monotherapy is used at high doses to maximize nitrogen excretion efficacy, then nitrogen excretion capacity is improved, but treatment cost increases significantly
Solution Approach 1:
The patent combines phenylbutyrate and benzoate into a unified treatment regimen, where benzoate serves as a cost-effective complementary agent that enhances overall nitrogen excretion capacity while reducing dependence on high-dose phenylbutyrate monotherapy
2Reliability
If phenylbutyrate is preferred over benzoate based on theoretical nitrogen-scavenging capacity, then nitrogen disposal capability is improved, but economic burden increases
Solution Approach 1:
The patent changes the therapeutic parameter from monotherapy with a single high-cost agent to combination therapy, adjusting the dosage ratios and administration protocols to optimize both clinical efficacy and cost-effectiveness
3Quantity of substance
If combination therapy with phenylbutyrate and benzoate is implemented, then treatment cost is reduced, but treatment complexity increases
Solution Approach 1:
The patent applies partial action by using moderate doses of both phenylbutyrate and benzoate rather than maximum doses, achieving sufficient nitrogen excretion while simplifying the treatment protocol and reducing monitoring requirements
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy demonstrates equivalent nitrogen excretion efficacy to higher-dose phenylbutyrate monotherapy, significantly reducing treatment costs while maintaining nitrogen-excretion capacity.
Implementation Method 1
Phenylbutyrate, a prodrug, is converted to phenylacetate (PAA) by β-oxidation; PAA conjugates with glutamine to form phenylacetylglutamine (PAGN)
Implementation Method 2
Benzoate combines with glycine to form hippuric acid (HA)
Data Source
AI summary
Embodiments of the disclosure include certain formulations for methods of treating urea cycle disorders. The methods encompass compositions that comprise benzoate and phenylbutyrate that may be at certain doses and have certain ratios of the components. The benzoate and phenylbutyrate may act synergistically in treatment of the urea cycle disorders, in particular embodiments.